Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACM-CpG Monotherapy in Advanced/Metastatic Solid Tumors
NCT06587295Phase 1Recruiting
- Sponsor
- National Cancer Centre Singapore
- Start
- Jan 2025
- Primary completion
- Dec 2026
- Modality
- Antisense DNA, Nanoparticles, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of ACM-CpG in solid tumor (2 arms), sponsored by National Cancer Centre Singapore. Primary endpoints: Maximum Tolerated Dose at 28 days, Recommended Phase 2 Dose up to 2 years and 11 more. Started Jan 2025; status: recruiting.
02
Drugs
ACM-CpG
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06587295.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06587295.